Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.
Once a poster child for a new generation of ambitious cell and gene therapy companies, bluebird bio has hit another setback in its efforts to bring its first product, Zynteglo, to market.
The company is down, not out, but its mounting problems in launching its innovative gene therapy will be a sobering...
Create an account to read this article
Already a subscriber?
With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.
The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.
Discover the latest trends in RNA-based therapeutics and learn how sponsors can successfully navigate the road to next generation innovation. Listen in as Citeline chats with the Director of Therapeutics at Novotech, a CRO experienced in RNA development.
An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.
